James Hutchings, Head of Sales for Bimeda UK, said: "The launch of Tetroxy Vet highlights our ongoing commitment to providing UK veterinarians with a choice of high quality veterinary pharmaceuticals at a fair price."
Bimeda says the benefits of Tetroxy Vet include:
Tetroxy Vet is available in a 100ml pack size.
Zesti comprises three ranges:
The Spirit range is a more standard looking scrub, manufactured from Alsi-Flex. The ‘Mode’ range looks a little more figure hugging, with an exclusive colour palette, and the Power range has a more sporting look.
Greg Houlston, General Manager, said: “Our healthcare workers need clothing that is practical and comfortable above anything else, yet our market research showed us that when it comes to scrubs with stretch, choice is limited in the UK compared with other markets such as the US.
“Veterinarians in particular need workwear that is especially hard wearing as the nature of their work means their clothing can be especially susceptible to rips, tears and soiling.
“We set out to create a brand that answered the need for more flexibility while challenging the perception that workwear should be dull and boring, and Zesti was born – a vibrant and contemporary range of garments, sustainably designed, to inspire confidence and positivity.”
Sara Catanzaro, Design Manager, added: “Our tailored garments offer exceptional attention to detail while being strong, hard wearing and resilient.
"They can be laundered domestically or industrially up to 60 degrees which is ideal for infection control.
"We’re already witnessing considerable demand as we believe we’ve hit the perfect balance between function and fashion.”
For more information, visit www.zesti.co.uk
Domingo, pictured on the left with Southfields clinical director Henry L’Eplattenier, will join the Essex referral centre as head of cardiopulmonary service at the start of February.
After qualifying in Zaragoza in his native Spain, Domingo completed an internship and several years in practice in the UK, before joining the University of Bristol small animal hospital as a resident.
He then completed a three-year training programme in small animal internal medicine, followed by a four-year programme in cardiology to become an RCVS diplomate and specialist in veterinary cardiology and small animal internal medicine (ECVIM).
After being appointed as head of cardiology and respiratory medicine at Bristol, Domingo joined Dick White Referrals before his move to Southfields.
Domingo said: "I’m delighted to be joining such a progressive and forward-thinking practice as Southfields. It is clear everyone at the practice is dedicated to continuing its growth and dedication to providing the highest possible level of care."
Southfields’ operations manager Daniel Hogan said: "The arrival of Domingo adds another hugely talented specialist to our growing team of experts. He is, without doubt, at the top of his profession and his passion and dedication are traits which will fit perfectly at Southfields as we continue to grow."
Domingo is also a visiting lecturer in cardiology and respiratory medicine at the Catholic University of Valencia, while he is an active clinical researcher and has published widely in many areas of cardiology and respiratory medicine. His areas of special interest are arrhythmias and interventional cardiology.
For more information about Southfields Veterinary Specialists, go to www.southfields.co.uk.
The Scottish Fold is bred for a cartilage abnormality which gives them their distinctive folded ears.
However, that same cartilage abnormality affects their joints, meaning that they go on to develop painful arthritis, even from a young age.
The charities say the impact of using this breed in a Hollywood film cannot be overstated and is likely to significantly increase their popularity with potential cat owners.
Nathalie Dowgray, Head of ISFM, said: “International Cat Care (iCatCare) and its veterinary division, the International Society of Feline Medicine (ISFM), believe that it is simply unethical to continue to breed cats with a genetic mutation that is known to cause significant painful disease – the rationale for breeding these cats was purely for traits considered attractive to humans, as some people believe the folded ears look appealing.
"This is an unnatural appearance for a cat, and the underlying genetic defect has far-reaching and severe consequences for the health of the cat.
"Health should always be more important than looks.”
The trailer for the film also shows a cat travelling in a backpack and subjected to rough handling, including being picked up by the scruff and thrown from a building.
ISFM says that although these scenes have been created using digital animation, the organisations share concerns that suggesting these interactions with cats are acceptable or entertaining may have a negative impact on the welfare of cats.
Sarah Ellis, Head of Cat Mental Wellbeing and Behaviour at International Cat Care, said: “Scruffing a cat is an unacceptable form of restraint that can cause a cat considerable discomfort, fear and even pain, as the weight of its body is completely unsupported, and the cat cannot escape the pressure from its skin being grasped.
"Backpacks are not a cat friendly way to transport a cat; they can leave a cat cramped, without enough ventilation, struggling to control body temperature, and uncomfortable due to the unpredictable movement from being worn on a person’s back.
"Backpacks are simply not cat friendly - they do not respect the cat as a species and run the risk of psychological and physical suffering to the cat.”
The organisations have contacted Universal Pictures, asking them to adopt Cat Friendly Principles in future, and not to promote cat breeds with extreme features in future.
Musculoskeletal therapists currently have their work underpinned by an Exemption Order to the Veterinary Surgeons Act 1966 which allows them to treat an animal under the direction of a veterinary surgeon who has first examined that animal.
The College says it has recognised that there has been confusion over whether musculoskeletal therapists need a veterinary referral for maintenance work, such as massage, in a healthy animal. This may lead to delays in animals receiving maintenance care.
The new guidance, found in Chapter 19 (www.rcvs.org.uk/unqualified) of the supporting guidance to the Code of Professional Conduct, sets out the existing rules for musculoskeletal treatment of illness, disease or pathology, and clarifies that healthy animals do not need a veterinary referral for maintenance care.
The guidance stresses that musculoskeletal therapists are part of the vet-led team, and that any animal, including healthy ones, should be registered with a veterinary surgeon and referred to a vet at the first sign of any symptoms that may suggest underlying health issues.
The guidance also says that vets should be confident that the musculoskeletal therapist is appropriately qualified; indicators of this can include membership of a voluntary regulatory body with a register of practitioners, and associated standards of education and conduct, supported by a complaints and disciplinary process.
In March 2019 the RCVS published the Review of Minor Procedures Regime (www.rcvs.org.uk/document-library/report-to-defra-on-the-review-of-minor-procedures-regime-and/) which noted that the existing exemption order was not suitable for underpinning the work of musculoskeletal therapists, and recommended that this be remedied by reform of Schedule 3 of the Veterinary Surgeons Act, alongside regulation by the RCVS through Associate status for musculoskeletal therapists.
This would allow the RCVS to set and uphold standards for musculoskeletal therapists in a similar way to veterinary nurses, giving further assurance to both the veterinary professions and the public. The recent Legislation Working Party Report recommendations builds on that recommendation, and is currently open for consultation at www.rcvs.org.uk/consultations
According to the College, other research suggests that comorbidities - such as anxiety and cognitive impairments - are common in dogs with epilepsy, meaning there is a need for new epilepsy management options which help to control seizures and improve behavioural and cognitive comorbidities.
Led by canine behaviour and welfare scientist Dr. Rowena Packer from the RVC and veterinary neurologist Professor Holger Volk from the University of Veterinary Medicine Hannover (TiHo), alongside RVC PhD student Dr. Benjamin Andreas Berk, the team of researchers tested the effects of an oil supplement on seizure frequency in dogs with drug-resistant epilepsy.
Multiple studies from the RVC have shown that medium chain triglyceride (MCT) oils-enriched diets can improve seizure control in difficult to treat, drug-resistant dogs with epilepsy. This controlled clinical study used non-invasive cognitive tests and a validated psychometric tool to show that dogs had improved spatial and working memory when treated with MCTs.
Dr Rowena Packer, Lecturer in Companion Animal Behaviour and Welfare at RVC, said: "Our ground-breaking research into the behavioural and cognitive comorbidities of canine epilepsy was the first to identify cognitive impairments in this population. We have now gone one step further and found a promising way to boost the impaired memories of these patients and reduce their seizure frequency, by a simple dietary change."
Professor Holger Volk, Department Chair for Small Animal Diseases at the University of Veterinary Medicine Hannover, said: "Our guts influence how well we think – this study highlights the importance of diets and the power of the gut-brain axis. We are just at the beginning of understanding how diets can influence complex diseases such as epilepsy and dementia. MCT oil could offer a promising addition to our management tool-kit."
Reference
Elanco is highlighting new research which shows that using monensin in dairy cows at high risk of developing subclinical ketosis reduces curative antibiotic use by 25%.
According to the company, good herd management before calving is known to mitigate antimicrobial use in cows suffering from subclinical ketosis related conditions, but to date little research has quantified it.
The new research, by the University of Toulouse, was presented to leading cattle vets, academics and representatives of the pharmaceutical industry by veterinary cattle health specialist, Professor Didier Raboisson at the European Buiatrics Forum in Rome in October.1 It showed that using a monensin bolus in cows at high risk of getting subclinical ketosis led to a 25% reduction in antibiotics to treat and cure conditions associated with the metabolic condition.
Fiona Anderson MRCVS of Elanco said: "Responsible use of antimicrobials must be the target for veterinary medicine. Reducing use by whatever means could help improve the antimicrobial resistance situation. This new study shows that using monensin, which is available in the form of a Kexxtone bolus, is a powerful way to cut antibiotic use in the dairy herd. This is in addition to monensin already proven to be a valuable tool to reduce the risk of ketosis and subclinical ketosis and its associated losses in dairy herd productivity and profitability."
Subclinical ketosis is very common. It can affect up to 30% of cows in early lactation with a large variation between herds.2 It can be very costly for a dairy herd. A study from 2015 found that for a 100 cow herd with 30% ketosis, the direct and indirect costs can be around £10,416 or around £347 per affected cow.3
Cows affected by subclinical ketosis are at a higher risk of getting mastitis and metritis. They are also at higher risk of developing displaced abomasum, retained placenta and cystic ovaries and consequently face a higher culling risk. Subclinical ketosis also lowers milk production, reduces conception rates and lengthens calving intervals.4
If ketosis is an issue in a dairy herd, targeted administration of monensin in a Kexxtone bolus to cows at high risk of developing ketosis reduces the incidences of ketosis by 74%.6
The bolus is given three weeks before calving and provides coverage during the main risk period for the condition. Kexxtone uses monensin to improve rumen function and increase glucose delivery. This ultimately increases the energy available and buffers the dairy cow against the tendency to drop into negative energy balance.5
To make a big difference to clients’ profitability, Fiona encourages vets to not just consider the traditional nutritional intervention and the emergency treatment of ketosis cases, but to develop an effective strategy to highlight cows at risk of subclinical ketosis and to take targeted preventative action. She said: "Vets who can offer positive interventions to subclinical ketosis and its associated losses in the dairy herd are going to be increasingly important to their clients’ herd health planning."
References:
Membra is a transparent, water-resistant, non-toxic, biodegradable bandage replacement consisting of a hydrogel polymer which can be applied to open wounds.
It is initially applied as a liquid and quickly gels into a thin, flexible layer over the site.
The initial liquid phase of Membra allows it to cover open and irregular spaces as well as suture lines and it dries in minutes to form a barrier that covers and protects the incision site or wound.
Being transparent, Membra allows the wound to be seen by the veterinary team and pet owners.
Membra lasts for up to 14 days and naturally biodegrades over time.
Animus says that Membra lowers the risk of infection or dehiscence.
The company also says that hydrogel polymer has been shown to replace the need for adhesive bandaging on suture lines following major TPLO surgery.
A study concluded that the polymer did not appear to raise the prevalence of incisional complications after TPLO surgery and lasts for 14 days, rather than 24-48 hours with traditional bandaging1.
Nick Butcher MRCVS, owner of Animus Surgical in the UK, said: “Regular bandaging of open wounds can be costly, time-consuming and stressful for owners and their pets, requiring frequent visits to the practice.
"The bandaging of some open wounds can be impossible because of the location of the lesion or the affected species (e.g. exotic or aquatic animals) and more aggressive or nervous patients may require sedation.
"Used bandages also add to the volume of clinical waste generated by the practice which requires incineration
“We are therefore delighted to launch Membra to veterinary teams in the UK.
"It has been very successful in the U.S. and we already have a number of UK vets using the product as Membra can positively affect the outcome of open wound management across a range of species, without the need for regular bandage changes.”
To find out how to apply Membra, a range of YouTube videos are available showing a selection of case examples: https://youtube.com/@sutureseal5917.
www.animussurgical.com.
The guidelines are designed to support veterinary surgeons, veterinary nurses and wildlife rehabilitators, in order to promote and achieve the best possible care and welfare for indigenous British wild animals in accordance with UK law.
The Society says that guidelines are needed because:
Mark Stidworthy, BVZS President (pictured above right), said: "The rescue and rehabilitation of wildlife by veterinary surgeons and wildlife professionals is highly valued by the British public, making a positive contribution to local communities, the health and welfare of individual animals and to conservation. We hope these guidelines will inform best practice in this area and ensure its continued success."
Theresa Amory, Chair of the British Wildlife Rehabilitation Council (BWRC) said: "BWRC aims to support and promote the professional integrity of wildlife rehabilitators. While we recognise that meeting all of these guidelines may be difficult (particularly for smaller scale rehabilitators) we hope that they will enable rehabilitators to work alongside veterinary partners with increased awareness and confidence in their own working policies and procedures."
Michael Stanford, BVZS Senior Vice President, Veterinary Defence Society Claims Consultant said: "The BVZS Wildlife Guidelines should ensure all stakeholders involved with wildlife rehabilitation are acting in the best interests of animal welfare, with the added reassurance that they are acting in accordance with UK law."
Liz Mullineaux, veterinary surgeon and one of the authors of the guidelines said: "Working with British wildlife has always been challenging, for both vets and rehabilitators, in terms of what is ethical, legal and of an adequate clinical standard. These guidelines clarify many of those things, describing best practice and achievable standards for this area of work."
The guidelines can be downloaded from: http://www.bvzs.org/images/uploads/BVZS_Good_Practice_Guidelines_for_Wildlife_Centres_011016_.pdf
Ceva Animal Health has added to its joint care range with the launch of Meloxidyl Oral Suspension for Cats, licensed for the treatment of musculoskeletal disorders and alleviation of post-operative pain.
Meloxidyl Oral Suspension for Cats is available in 15ml bottles containing 0.5mg/ml meloxicam. Each pack contains a tailored maintenance dosing syringe with a 'kg scale' for all sizes of cat. In addition, Meloxidyl's sweet tasting formulation helps to maximise ease of administration.
Meloxidyl Injection complements Ceva Animal Health's joint care range, which also includes Meloxidyl Injection for dogs and cats and Meloxidyl Oral Suspension for dogs.
For further information, please contact your Ceva Animal Health representative or call 01494 781510.
400 people took part in the research, of which 76% described their mental health as ‘reasonable’ or ‘very good’, while almost three quarters 71% said there was someone at work they could talk to about their mental health and 80% knew where to access information and support.
This compared to 2019, when only 50% had even recognised veterinary wellbeing as an issue.
So far so good.
However, on the flip side, 60% felt that their work/life balance was not right and 82% were worried about their financial situation.
As is well known, the pandemic placed further strain on veterinary professionals: 78% of respondents said their workload had increased since it struck, and 44% said they were working longer hours.
What's more, 63% felt that that changes in working practices introduced during the pandemic had not been beneficial to their mental health.
The survey results showed a number of interesting variations depending on the respondent's time in the profession and their role.
For example, people who've been in the profession for more than ten years appeared to be more resilient than those who've been in the profession for six years or less, with 66% of the older hands saying the pandemic had had an impact on their mental heath, compared to 71% of the younger respondents.
The older crowd also reported being more aware of where to access support and information (89% vs 71%) but feel they have fewer people they can talk to at work (68% vs 76%).
Interestingly, nurses felt they had more people they can talk to at work (76% vs 62% of vets)
The organisers say that overall, the research suggests that the veterinary profession is more aware of the pressures on veterinary teams and is taking some steps to mitigate it and support staff better.
97% said they felt supported by their colleagues, 75% said they felt that their practice had strong leaders and managers and 90% said that they loved their job.
50% said their practice offers online resources to support wellbeing at work, 41% offer counselling and 40% offer flexible working.
When asked what more could be done to improve their wellbeing at work, simple solutions such as taking a lunch break, having a pleasant room at work in which they could relax and receiving recognition for hard work were the most commonly proposed.
VET Festival will be offering a Wellness Hub, supported by MWI Animal Health, in which a range of practical activities will be offered to support delegates in improving their day-to-day wellbeing, with representatives of Vetlife also on hand to offer advice and support.
Tickets for VET Festival can be bought here: https://www.vetfestival.co.uk/delegate-info/ticket-information
Zoetis has launched a 4ml vial of the antibiotic, Convenia.
Zoetis says Convenia gives veterinary surgeons control by providing an assured injectable treatment course, relieving clients of the burden of daily dosing. This avoids missed or mistimed doses, lost tablets, or courses stopped too soon, thereby eliminating a major reason for treatment failure, non-compliance. Poor compliance is also a significant factor in the development of antimicrobial resistance.
Convenia is licensed for skin, soft tissue and urinary tract infections in dogs and cats, as well as severe gingivitis/periodontitis in dogs (as an adjunct to mechanical or surgical periodontal therapy). A 4ml vial can treat up to 40kg of bodyweight, making it appropriate for treating cats and smaller dogs.
Zoetis says that the launch of the new vial demonstrates its commitment to the 'Respect Antibiotics' campaign launched last year. The Respect Antibiotics campaign encourages careful and informed selection of appropriate antibiotic therapies for the treatment of dogs and cats.
Product Manager, Andrew Page, said; "We are committed to encouraging responsible antibiotic usage, and reducing the incidence of antibiotic resistance. Non-compliance plays a key role in the development of antibiotic resistance and we hope that by making Convenia more accessible through the introduction of a 4ml vial we can help alleviate compliance issues."
For further details about Convenia please contact your Zoetis Account Manager.
Furosoral contains furosemide and is indicated for the treatment of hydrothorax, hydropericardium, ascites and oedema, particularly in animals where these conditions are associated with cardiac insufficiency and renal dysfunction.
Furosoral replaces Dechra’s previous diuretic treatment, Frusedale.
It is available in both 10 mg and 40 mg double-divisable tablets.
The recommended daily starting dose for cats and dogs is 2.5 mg per kg of body weight.
Dechra says careful weighing is essential to ensure accurate dosing, but that the dosage can be doubled initially for severe or particularly resistant cases and adjusted to the lowest clinically effective dose for maintenance therapy if required.
Dechra companion animal brand manager, Charlotte Hill, said: “Furosoral offers a flexible treatment solution where dosage can be adjusted, depending on the needs of the patient and the underlying causes, to give vets more options for treating cats and dogs with fluid retention.
“To ensure it is as appealing to pet owners as it is to veterinary professionals, Furosoral is available in our innovative Smart Tab format, giving owners confidence that they are giving their dog or cat the right dosage and aiding compliance, leading to better outcomes for the animal.”
Furosoral 10 mg and 40 mg tablets are available in blister packs of 100 tablets for quick and easy dispensing. Divided tablets can be stored in the blister pack for up to three days, ensuring no waste.
https://www.dechra.co.uk/products/dog/prescription#/search=furosoral/.
Led by clinicians from Davies Veterinary Specialists, the Royal Veterinary College, and Willows Veterinary Centre and Referral Service, the study assessed the proportion of metronidazole use that was prescribed for non-antimicrobial purposes, and the rationale for it.
A survey was completed by 138 veterinarians, primarily in the UK and working in primary care small animal practice, who treated 332 cases (285 dogs and 47 cats) with metronidazole.
In 42% of cases, metronidazole was selected exclusively for non-antimicrobial targeted therapy, and was most commonly prescribed to treat acute diarrhoea, chronic diarrhoea, or giardiasis.
This, say researchers, is despite recommendations that antimicrobials are very rarely warranted for the management of acute and chronic diarrhoea.
The most common rationale cited by vets to justify metronidazole use was its supposed anti-inflammatory or immunomodulatory properties.
Other reasons included: treatment of suspected or confirmed anaerobic or susceptible bacterial infection, the patient being systemically unwell or having severe disease, treatment of protozoal infections, experiencing a previous positive outcome in a similar case or the same patient, anti-diarrhoeal action and owner or practice expectations.
Dr Justin Ng, lead author of the study, said: “These insights are alarming given that such practices frequently deviate from current antimicrobial use guidelines, potentially contributing to ongoing challenges with antimicrobial resistance and adverse effects on gastrointestinal health.”
https://onlinelibrary.wiley.com/doi/10.1111/jsap.13910
The webinar, which takes place on Thursday 30th June at 7.30pm, is being presented by Debbie Boone, billed as one of America’s most prominent and experienced veterinary communications consultants.
Gerrard Harkins, Premier Vet Alliance’s Commercial Director said: “Many people struggle with managing challenging behaviour and confrontation in the workplace and Debbie will be focusing on providing delegates with pragmatic advice and skills to put into practice.
"She is one of the veterinary industry’s most prominent and successful communicators so we’re extremely fortunate to be able to access her advice.
“We’re also looking forward to gaining a US perspective on this important subject.”
To register for the webinar, visit: https://tinyl.io/5aIk
At his first Disciplinary Committee hearing in January 2018, the Committee directed that Dr Gerhard Schulze Allen’s name be removed from the Register after finding him guilty of serious professional misconduct in respect of four charges against him. These related to an incident of petty theft in California in the United States, and his subsequent dishonesty in not disclosing this to the College.
Following the Disciplinary Committee hearing, Dr Schulze Allen submitted an appeal to the Privy Council. In July 2019, the Privy Council partially upheld his appeal, determining that the RCVS had not proven beyond all reasonable doubt that Dr Schulze Allen’s infraction for petty theft was a conviction under Californian law and therefore Dr Schulze Allen had not made false representations to the College when he said he did not have any criminal convictions or a criminal record.
However, the Privy Council partially upheld the College’s charge that Dr Schulze Allen was dishonest and made false representations when he had, in a written application for restoration to the Register, represented that he did not have any adverse findings and that he should have declared his infraction for petty theft. The Privy Council also set aside the Disciplinary Committee’s original sanction and remitted the task of sanction back to the Disciplinary Committee.
As a result of the Privy Council’s decision, the Disciplinary Committee held a further hearing in relation to Dr Schulze Allen to decide the sanction in relation to the upheld charge against him.
The Committee noted that the aggravating factors were the fact that Dr Schulze Allen was dishonest to his regulator and in making a false declaration, demonstrated a wilful disregard for the regulatory role of the RCVS. In mitigation the Committee considered that there was no harm to animals, that it was a single and isolated incident in an otherwise unblemished career, and that he had accepted his wrongdoing, albeit at a late stage, and was developing some insight.
The Committee considered whether a reprimand or warning would be the most appropriate sanction but determined that this would not reflect the seriousness of the dishonesty in this case, nor maintain public confidence in the profession or uphold proper professional standards of conduct and behaviour.
Ian Green, chairing the Committee and speaking on its behalf, said: "The Committee concluded that the appropriate and proportionate sanction is suspension from the Register for a period of three months. A period of three months reflects the seriousness of the charge. Such a sanction sends a clear message to Dr Schulze Allen, the profession and the public that behaving dishonestly towards the regulator is a serious matter. The Committee considered that removal from the Register would be disproportionate given that this is a single incident and Dr Schulze Allen now accepts his wrongdoing."
In the study titled “Outcomes of treatments for keratomalacia in dogs and cats: a systematic review of the published literature including non-randomised controlled and non-controlled studies”, a systematic review of the current literature was undertaken to determine the evidence base for the various treatments of keratomalacia in dogs and cats.
The aim of the review was to assess the evidence base and identify recommended treatment(s) based on globe survival, visual outcome, and time to resolution (while maintaining a globe).
An online literature search found 18 relevant studies which were then reviewed and assigned a level of evidence base as described in the Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working Group.
Each study was assessed for type of study described (e.g. retrospective, prospective, controlled, random/non-random, cohort study, case series/study), the number of animals included, criteria for assessing outcome (e.g. vision, corneal clarity, anatomic repair) and duration of follow-up and time to resolution.
Systematic reviews of randomised trials, randomised trials or observational studies with dramatic effects would have provided the most reliable evidence on which to base recommendations for treatment(s) but none were available for inclusion.
Only one study was classified as level 3 evidence (non-randomised controlled trial) and considered the use of corneal cross-linking (CXL) in the treatment of keratomalacia.
Most studies were level four evidence reporting the outcome of a single treatment, with three prospective studies and seven retrospective studies.
The remaining seven studies were level five evidence (mechanism-based reasoning) and were considered not to provide good evidence for answering the particular study question.
The findings of the study suggest that the evidence for improved outcome of one proposed treatment over another proposed treatment for keratomalacia in dogs and/or cats is very weak.
A combination of treatments – both medical and surgical – may be the most appropriate depending on the individual case.
Studies utilising mechanism-based reasoning would suggest that medical treatment with anti-collagenase treatment is a minimum requirement for keratomalacia cases to prevent globe loss through perforation, with associated pain and suffering.
Nicola Di Girolamo, Editor of JSAP, said: “The findings of this study highlight once more the infrequency of randomised controlled trials in the veterinary literature, and the need for such studies to expand the evidence base in this field.
“Focussing on collecting available evidence in well-conducted systematic reviews is a critical step in order to improve accessibility of the literature for general practitioners and specialists alike.”
The full article can be found in the October issue of the Journal of Small Animal Practice and can be read online here: https://onlinelibrary.wiley.com/doi/10.1111/jsap.13326. It is open access and can be freely accessed by anyone.
Photo courtesy BSAVA
Apoquel chewable tablets were approved by the Veterinary Medicines Directorate (VMD) in November 2021.
Apoquel Chewable contains the same active ingredient, at the same dosing regime, for the same indications as original Apoquel, but in a palatable formulation which, in a field-study of client-owned dogs, was found to have a 91.6% acceptance rate.1
Dr Carly Mason, President of the British Veterinary Dermatology Study Group (BVDSG), said: “The new chewable form of Apoquel provides owners with a means of controlling itch using a tablet that can be given like a treat or mixed with a meal, making it much easier for owners and more acceptable to their pet.
“In many cases, the chewable formulation will be the obvious first-line Apoquel for veterinarians to prescribe to control canine itching while the underlying cause of allergic dermatitis is investigated.”
Elanco Companion Animal Health has launched a novel prescription flea treatment for dogs which, according to the company, combines a rapid kill rate with convenient monthly oral administration.
Elanco says Comfortis Chewable Tablets for Dogs start to kill fleas within 30 minutes, providing 100 per cent control in four hours, the fastest specific claim of any approved flea preventive.
The product is based on a unique active ingredient, Spinosad, a naturally occurring fermentation product of soil bacteria with a unique insecticidal effect. Since its launch in the United States in 2007, Comfortis has established itself as the number one recommended prescription flea medication in that country and has now received European authorisation.
Elanco says the combination of its rapid action and oral method of administration is expected to prove particularly helpful in cases including:
Jannes Nijland, marketing and innovation director for Elanco Companion Animal Health in Western Europe, said: "The veterinary profession has indicated a strong desire for a prescription only flea treatment. While vets remain the 'first port of call' for advice on flea medication, our research shows that only 42 per cent of dog owners still buy their treatments from practices. We believe that the launch of an alternative approach to flea control available from practices could help vets strengthen their client relationships."
He added: "Comfortis is the first product developed and launched by Elanco Companion Animal Health in Western Europe. It is a perfect demonstration of how we intend to deliver on our mission to help veterinarians help pets live longer, healthier and higher quality lives."
For further information about Comfortis, veterinary practices should contact their Elanco key account manager, or to contact the company directly on 01256 779881
Additional information about Elanco is available at www.elanco.com and the company can be contacted via email at elancoCAH.uk@lilly.com
Ceva Animal Health has launched a new broad-spectrum, flavoured endoparasiticide tablet, Milbactor for dogs.
Milbactor contains milbemycin oxime and praziquantel, which offer protection against the common nematodes seen in the UK and the main species of tapeworm.
Milbemycin oxime treats Toxocara canis and Toxascaris leonina, Angiostrongylus vasorum and Crenosoma vulpis, the hookworm Ancylostoma caninum, the whipworm Trichuris vulpis and the eyeworm, Thelazia callipaeda. Milbactor also prevents heartworm disease caused by Dirofilaria immitis.
Praziquantel protects against Echinococcus spp., Dipylidium caninum, Taenia spp. and Mesocestoides spp.
Puppies weighing more than 0.5 kg can be treated with Milbactor from two weeks of age. Milbactor comes in two tablet sizes for dogs and puppies, and the tablets are flavoured for easy administration.
Ceva has also launched The Ceva Protection System for dogs, a two-step solution featuring Vectra 3D and Milbactor to provide ectoparasite and endoparasite protection for dogs with one monthly topical treatment and one flavoured tablet. The Ceva Protection System uses Vectra Felis for flea protection for cats and Acclaim for the treatment of the pet's home environment.
Rob McLintock MRCVS, companion animal business unit manager at Ceva Animal Health, said: "The launch of Milbactor and The Ceva Protection System will enable veterinary surgeons to offer their clients a simple regime featuring Vectra 3D and Milbactor for comprehensive parasite control in dogs. Offering protection both inside and out and with no bite required to kill fleas, the regime offers a simple, effective combination to treat and prevent fleas, ticks, biting flies, roundworms, tapeworms, lungworms and to prevent heartworm.
For further information on The Ceva Protection System, Milbactor, Vectra 3D or Vectra Felis, contact your local Ceva territory manager or call 01494 781510.
Reverse wound bandages are made with the adhesive on the outside and design printed on the inside, making it easier to apply the bandage without over-tightening.
The company says it has launched the new reverse-wound bandage in response to demand from veterinary practices.
The bandages come in two widths: five and 7.5 cm, in a range of colours and designs which were chosen by veterinary nurses. They are 2.2m long, stretching to 4.5m, and J.A.K Marketing says they are super flexible, lightweight and easy to tear.
For more information, visit: https://www.jakmarketing.co.uk/products/aniwrap-sketch.html
Creature Comforts will be using the cash both to open the clinics and build a proprietary app which will give owners seamless 24/7 access to veterinary care, whilst allowing vets to work more flexibly and more often from home.
VetSurgeon.org caught up with Russell Welsh (pictured), co-founder of the new business alongside Daniel Attia.
Russell said: "During the pandemic, there was a recognition that employers needed to do more to attract and retain veterinary staff, and so there has been a move towards more flexible working and better employment packages.
"The problem is that we then saw a massive increase in the number of pets, and the profession is struggling to meet demand.
"On top of that, the corporatisation of the profession has meant that both staff and owners often feel less connected with each other.
"We think the answer lies in independent practices making better use of technology to reduce the workload on veterinary staff whilst creating a better, seamless, more personal experience for pet owners.
"There are of course companies offering online consultations, but they tend to be stand alone services, or belong to corporate groups.
"What we're doing differently is developing our own system so that we don't lose control of any stage in the client journey and can make sure the quality of care, after care and service is consistently high.
"We'll also be putting together a share option scheme, so our employees will really feel a proper sense of ownership."
https://www.creaturecomforts.co.uk
Bayer Animal Health has launched four short youtube films about parasites, fronted by celebrity veterinary surgeon, Scott Miller.
The press blurb says the films "will provide pet owners with an amazing and educational journey into the world of parasites and highlight the need for the control of these often unwelcome pests", which I would normally translate as: "will provide anyone with too much time on their hands with a rather dull five minute advertisement for our flea treatment".
But no. The big surprise is that in addition to the slick production values, these films actually are rather interesting. I've just watched the first, and learned a bit about the vampire bat. There's some compelling infra-red footage of some of them feeding on a sleeping horse.
Elsewhere in the You Tube clips, Scott discusses other parasites including fleas, ticks and worms, and shows the harm they can inflict if owners don't sufficiently protect their cats and dogs with appropriate treatments. On that score, he urges owners to seek veterinary advice. Scott also discusses the threats posed by the increasing urbanisation of foxes and by exotic diseases that are now being found much further north as a result of climate change.
Matt Frost, UK marketing manager at Bayer Animal Health, says: "The clips, all of which are around four minutes in length, provide an opportunity for pet owners to learn more about parasites in a novel and entertaining way. We hope that viewers will learn more about the inherent dangers some of these creatures pose to pets and the steps that can be taken to protect against them.
The other clips can be viewed online at www.youtube.com/user/parasitesundercover1. You might even like to embed them from youtube into your own practice website.
The RCVS Disciplinary Committee has removed a veterinary surgeon formerly working in Lincolnshire from the Register, after finding him guilty of serious professional misconduct for drink-driving related convictions, failing to inform his employer of these convictions, and driving whilst disqualified.
Jaroslaw Slominski, a former employer of Grants Veterinary Services plc, chose not to attend the three-day hearing. The Committee considered whether to proceed with the case, using criteria identified by the Court of Appeal in R v Jones (Anthony) in 2002 and confirmed by the House of Lords. It concluded it was in the interests of justice that the hearing should go ahead.
The charges related to two convictions Mr Slominski received on 17 March 2010 at Lincoln Magistrates Court: failure to provide a specimen of breath for analysis and driving without due care and attention (after his vehicle collided head-on with another car). Mr Slominski failed to inform his employers of these convictions, as he was contractually obliged to do, and that he was now disqualified from driving.
Having heard evidence from Mr Slominski's line manager, the Committee also found that he had driven his employer's vehicle whilst disqualified, although it could not be sure that he had done so on all the occasions alleged. Therefore, the Committee did not go on to consider an alternative part of the charge - that Mr Slominski had dishonestly claimed money from his employer by falsely submitting expenses claims.
Disciplinary Committee Chairman Prof Peter Lees said: "The combination of factors in this case, namely, the serious nature of his conviction in failing to provide a specimen of breath, his subsequent premeditated conduct in not informing his employers and driving whilst disqualified should be treated by the profession very seriously. The Committee has concluded that the combination of the conviction and the conduct is incompatible with Mr Slominski practising as a veterinary surgeon."
The Committee directed that Mr Slominski's name be removed from the Register.
It has long been known that diabetes is a disease that requires an individualized treatment protocol in order to manage the condition. The Insuvet range includes Insuvet Lente with medium duration and onset, Insuvet Protamine Zinc with longer duration and onset (an ideal choice for some cat owners who may find twice daily injections problematic), and Insuvet Neutral, which should be kept in every practice to manage acute diabetic ketoacidosis.
Susan Mitchell, Insuvet Product Manager said: "A flexible approach allows patients to be managed more effectively; both from the point of view of the patient's needs but also those of the owner too. People have increasingly busy schedules and providing a solution that fits with lifestyle and helps deal with any diabetic crises that do occasionally occur, will ensure successful long term management of the condition."
The team at Pfizer has been busy undergoing intensive technical training and is equipped to provide assistance with diabetic cases. Regional support is now available in the shape of dedicated Area Veterinary Managers who can provide practices with comprehensive support, backed up with a national technical support helpline.
The company has available a wide range of support materials that include stabilisation protocols, blood glucose monitoring charts and communication aids that explain the condition to the client, with the promise of an even more comprehensive range of exciting and innovative aids to come in the next few months.
For further information on the Insuvet range vets and nurses should contact their Pfizer Business Account Manager. For advice on individual cases or any other technical questions about diabetes call the Technical Support Line on 0845 3008034.